On Demand Pharmaceuticals Commissions State-of-the-Art, cGMP Medicine Manufacturing Facility
The CGMP facility represents a critical first step in a new era of drug manufacturing aimed at strengthening domestic supply chain resiliency
The CGMP facility represents a critical first step in a new era of drug manufacturing aimed at strengthening domestic supply chain resiliency
Neurophth Biotechnology Ltd., a fully-integrated genomic medicines company seeking to improve lives through the curative potential of gene therapies, announced the opening of its state-of-the-art manufacturing facility at the Phase II Suzhou Biomedical Industrial Park (BioBAY) in Suzhou, China.
The new, state-of-the-art manufacturing facility, operated by Heritage Pharma Labs Inc. (“Heritage Pharma Labs”), consists of dispensaries/pharmacies and multiple manufacturing suites to hold fixed and portable equipment to perform pharmaceutical operations like mixing, granulation, drying, milling/sieving, compaction, extrusion/spheronization, blending, compression, coating, encapsulation and packaging